Grape Seed Powder and Vitamin C Supplementation for Liver Disease (Acquired Hepatic Jaundice)

Jaundice is a frequent medical problem that affects people of all ages. It is important to note that jaundice is not an actual sickness as such itself but rather a symptom of liver illness brought on by an increase in the quantity of bilirubin circulating in the blood owing to improper metabolism and excretion in the urine. The aim of this investigation is to investigate the impact of grape (Vitis Vinifera) seed powder along with vitamin C supplementation on serum bilirubin levels in patients with acquired hepatic jaundice. In addition, it's the first research of its kind to investigate the aforementioned function of grape seed extract with vitamin C in healthy individuals specifically.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Jaundice Hyperbilirubinemia Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms Skin Manifestations

Age range

20 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Lahore

Lahore, Punjab Province, Pakistan

About this study

According to my study, the division of patients was done between two groups: one was named as Conventional group (CG) and other was named as Intervention group (IG). The conventional treatment group received only conventional medication and intervention group was given Grape-C capsule with dose of one tablet per day for 4 weeks after lunch along with conventional medication. Grape-C capsule continued for 4 weeks and the data was obtained at the initiation and at end of intervention (after 4th week).

According to my research study results the intervention group had a significant decrease in bilirubin levels, ALT, AST, ALP and increase the albumin and gamma glutamyl transferase (GGT) compared to the conventional group. The p-values for the comparison between pre and post intervention levels were highly significant rather than the conventional groups indicating a statistically significant difference.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Both men and women
Participants between the ages of 20-40 years will be included
Patients having signs and symptoms of acquired hepatic jaundice
Patients having high serum bilirubin, albumin, ALT, AST, ALP levels
The patient having ALT level more than 10-50 U/L were included
The participants having AST level above than 0-40 IU/L were included in this study
Patients having ALP level more than 30 - 130 U/L were included in this research study
Patients having level of bilirubin above than 0 - 21 μmol/L were included in this investigation
Participants having the range of albumin more than 30-50 g/L were included in this research
Participants those were underweighted were included

Exclusion criteria

Patients who already taking any supplement or medication
Participants taking any anti-inflammatory medications
People who were suffering from any other disease
Patients who have any known allergies
Non willing patients
Lactating women
Pregnant women
Smokers

Treatment and study plan

Grape-C supplement

Dietary Supplement

Grape-C supplement purchased from Nutrifactor brand.

Primary outcomes

Bilirubin levels

Time frame: 4 weeks

In this study results showed the significant decrease in bilirubin levels in interventional group as compared to the conventional group

Sponsors and collaborators

Lead sponsor

University of Lahore Hospital (ULH)

Network

Registry information

Official study title

Impact of Grape (VITIS VINIFERA) Seed Powder Along With Vitamin C Supplementation on Serum Bilirubin Levels in Patients With Acquired Hepatic Jaundice

Acronym: AHJ

Important dates

Study start: 2023
Primary completion: 2023
Study completion: 2023
First posted: May 8, 2026
Registry last updated: May 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed